1,514
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment

, , , , , , , , , , , , , & show all
Article: e1168549 | Received 23 Nov 2015, Accepted 16 Mar 2016, Published online: 08 Jun 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Golnaz Vaseghi, Ahmad Ghasemi, Ismail Laher, HojjatAllah Alaei, Nasim Dana, Hajar Naji esfahani & Shaghayegh Haghjooy Javanmard. (2023) Morphine upregulates Toll-like receptor 4 expression and promotes melanomas in mice. Immunopharmacology and Immunotoxicology 45:3, pages 347-354.
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now

Articles from other publishers (11)

Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie & Yuhua Li. (2021) Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomarker Research 9:1.
Crossref
Sze Wah Samuel Chan, Elliot Smith, Reenika Aggarwal, Karmugi Balaratnam, RuiQi Chen, Katrina Hueniken, Rouhi Fazelzad, Jessica Weiss, Shirley Jiang, Frances A. Shepherd, Penelope A. Bradbury, Adrian G. Sacher, Natasha B. Leighl, Wei Xu, M. Catherine Brown, Lawson Eng & Geoffrey Liu. (2021) Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer 22:5, pages 390-407.
Crossref
M. S. Sinto, Shaji Thomas & S. Kannan. (2021) Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis. Medical Oncology 38:9.
Crossref
Jian-Zhao Xu, Chen Gong, Zheng-Fu Xie & Hua Zhao. (2021) Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma. Frontiers in Oncology 10.
Crossref
Neng Wang, Shengqi Wang, Xuan Wang, Yifeng Zheng, Bowen Yang, Juping Zhang, Bo Pan, Jianli Gao & Zhiyu Wang. (2021) Research trends in pharmacological modulation of tumor‐associated macrophages. Clinical and Translational Medicine 11:1.
Crossref
Foteinos-Ioannis D. Dimitrakopoulos, Anastasia E. Kottorou, Melpomeni Kalofonou & Haralabos P. Kalofonos. (2020) The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer. Cancer Research 80:19, pages 4025-4036.
Crossref
Anqi Lin, Ting Wei, Hui Meng, Peng Luo & Jian Zhang. (2019) Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Molecular Cancer 18:1.
Crossref
Yijun Jia, Xuefei Li, Tao Jiang, Sha Zhao, Chao Zhao, Limin Zhang, Xiaozhen Liu, Jinpeng Shi, Meng Qiao, Jiawei Luo, Sangtian Liu, Ruoshuang Han, Chunxia Su, Shengxiang Ren & Caicun Zhou. (2019) EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies. International Journal of Cancer 145:5, pages 1432-1444.
Crossref
Spiros Vlahopoulos, Maria Adamaki, Nikolas Khoury, Vassilis Zoumpourlis & Istvan Boldogh. (2019) Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. Pharmacology & Therapeutics 194, pages 59-72.
Crossref
Jinming Yang, Amrendra Kumar, Anna E. Vilgelm, Sheau-Chiann Chen, Gregory D. Ayers, Sergey V. Novitskiy, Sebastian Joyce & Ann Richmond. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunology Research 6:10, pages 1186-1198.
Crossref
Allyson G. McLoed, Taylor P. Sherrill, Dong-Sheng Cheng, Wei Han, Jamie A. Saxon, Linda A. Gleaves, Pingsheng Wu, Vasiliy V. Polosukhin, Michael Karin, Fiona E. Yull, Georgios T. Stathopoulos, Vassilis Georgoulias, Rinat Zaynagetdinov & Timothy S. Blackwell. (2016) Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer. Cell Reports 16:1, pages 120-132.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.